This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Core Insights - Kynam Capital Management reduced its stake in Viridian Therapeutics by 2,957,386 shares in Q4 2025, with an estimated transaction value of $81.11 million based on average pricing [2][4] - The value of Viridian's stake declined by $49.79 million at quarter-end, reflecting both trading and market price effects [2] - Viridian Therapeutics is a clinical-stage biotechnology company focused on developing innovative antibody-based therapies, particularly for thyroid eye disease [6][9] Company Overview - Current stock price of Viridian Therapeutics is $26.98, with a market capitalization of $2.8 billion [4] - The company reported a total revenue of $70.79 million and a net income loss of $342.6 million over the trailing twelve months [4] - Viridian's pipeline includes monoclonal antibody therapies targeting serious diseases, with a focus on thyroid eye disease [9] Financial Performance - Kynam Capital's stake in Viridian now represents 2.92% of its 13F reportable assets under management [8] - Viridian shares have increased by 76% over the past year, significantly outperforming the S&P 500's 15% gain during the same period [8] - The company is facing high research and development costs, nearing $339 million, with a full-year net loss of approximately $343 million [10] Upcoming Milestones - Viridian is approaching a critical period with a PDUFA date for veligrotug on June 30 and multiple Phase 3 readouts for VRDN-003 expected this year [10] - The company has a strong balance sheet with approximately $875 million in cash at year-end, which helps mitigate financial risks [10]